We are live on
!
Find out more
Squarepoint Portfolio holdings
AUM
$85.1B
1-Year Est. Return
20.93%
This Fund
S&P 500
This Quarter
Est. Return
+5.99%
1 Year Est. Return
+20.93%
3 Year Est. Return
+51.38%
5 Year Est. Return
+34.63%
10 Year Est. Return
+146.23%
AUM
$63.9B
AUM Growth
+$3.43B
(+5.7%)
Cap. Flow
+$105M
Cap. Flow
% of AUM
0.16%
Top 10 Holdings %
Top 10 Hldgs %
21.18%
Holding
4,866
New
886
Increased
1,406
Reduced
1,667
Closed
823
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$3B |
| 2 |
Microsoft
MSFT
|
+$508M |
| 3 |
State Street Real Estate Select Sector SPDR ETF
XLRE
|
+$209M |
| 4 |
iShares MSCI Emerging Markets ETF
EEM
|
+$190M |
| 5 |
Qualcomm
QCOM
|
+$167M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$711M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$184M |
| 3 |
Oracle
ORCL
|
+$168M |
| 4 |
Gilead Sciences
GILD
|
+$140M |
| 5 |
Snowflake
SNOW
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 8.98% |
| 2 | Consumer Discretionary | 6.34% |
| 3 | Financials | 4.35% |
| 4 | Healthcare | 4.2% |
| 5 | Industrials | 3.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3926
Pacific Biosciences
PACB
$422M
| $73.2K | ﹤0.01% |
43,040
-481,568
| -92% | -$791K |
|
3927
Matinas BioPharma
MTNB
$1.55M
| $72.9K | ﹤0.01% |
+20,601
| New | +$131K |
|
3928
iHeartMedia
IHRT
$535M
| $72.3K | ﹤0.01% |
39,057
+21,396
| +121% | +$31.9K |
|
3929
Nordic American Tanker
NAT
$1.37B
| $72.2K | ﹤0.01% |
+19,684
| New | +$72.3K |
|
3930
Candel Therapeutics
CADL
$700M
| $71.7K | ﹤0.01% |
10,349
-1,889
| -15% | -$11.7K |
|
3931
SOPHiA GENETICS
SOPH
$480M
| $71.4K | ﹤0.01% |
+19,639
| New | +$79.8K |
|
3932
Westwater Resources
WWR
$51M
| $70.4K | ﹤0.01% |
136,450
-193
| -0.1% | -$98 |
|
3933
BARK
BARK
$74.8M
| $69.9K | ﹤0.01% |
+2,144
| New | +$69.8K |
|
|
HLVX
3934
DELISTED
HilleVax
HLVX
| $68.6K | ﹤0.01% |
+38,967
| New | +$99.9K |
|
|
ADAM
3935
Adamas Trust
ADAM
$777M
| $68.4K | ﹤0.01% |
10,813
-12,497
| -54% | -$80.4K |
|
3936
MarketWise
MKTW
$53.1M
| $68.2K | ﹤0.01% |
5,100
-1,159
| -19% | -$21.3K |
|
|
3937
CALL
Pacific Biosciences
PACB
$422M
| $68K | ﹤0.01% |
+40,000
| New | +$65.7K |
|
|
EFXT
3938
Enerflex
EFXT
$2.78B
| $65.7K | ﹤0.01% |
+11,020
| New | +$61.8K |
|
3939
CEMIG Preferred Shares
CIG
$6.09B
| $65.6K | ﹤0.01% |
31,853
-15,411
| -33% | -$30.7K |
|
3940
Holley
HLLY
$314M
| $64.6K | ﹤0.01% |
21,903
-114,892
| -84% | -$385K |
|
3941
PMV Pharmaceuticals
PMVP
$66.1M
| $64.5K | ﹤0.01% |
43,293
-7,831
| -15% | -$12.1K |
|
3942
Corvus Pharmaceuticals
CRVS
$1.1B
| $63.8K | ﹤0.01% |
+12,080
| New | +$43.4K |
|
|
MKFG
3943
DELISTED
Markforged Holding Corporation
MKFG
| $63.5K | ﹤0.01% |
13,309
-1,239
| -9% | -$4.02K |
|
|
ENZ
3944
DELISTED
Enzo Biochem, Inc.
ENZ
| $63.4K | ﹤0.01% |
+56,646
| New | +$63.4K |
|
3945
Genelux
GNLX
$130M
| $63.2K | ﹤0.01% |
26,657
-11,607
| -30% | -$25.6K |
|
3946
MeiraGTx Holdings
MGTX
$1.09B
| $63.2K | ﹤0.01% |
15,146
-14,103
| -48% | -$61K |
|
3947
Adaptive Biotechnologies
ADPT
$3.56B
| $62.2K | ﹤0.01% |
+12,154
| New | +$53K |
|
3948
CALL
Joby Aviation
JOBY
$6.82B
| $61.9K | ﹤0.01% |
12,300
-115,100
| -90% | -$626K |
|
|
ONTF
3949
DELISTED
ON24
ONTF
| $61.8K | ﹤0.01% |
10,091
-60,890
| -86% | -$377K |
|
3950
Sabre
SABR
$656M
| $61.3K | ﹤0.01% |
+16,709
| New | +$51.9K |
|
Similar funds
Squarepoint's Q3 2024 Portfolio in Review
As of Q3 2024, Squarepoint held 4,866 positions worth $63.9B, up 5.7% from $60.5B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Squarepoint's Q3 2024 filing shows 886 new, 1,406 increased, 1,667 reduced and 823 closed positions. Its largest new stake was State Street Real Estate Select Sector SPDR ETF: 4,950,000 shares worth $221M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $711M.
By sector, the portfolio is most concentrated in Technology at 9% of assets, down from 9.1% a quarter earlier, followed by Consumer Discretionary and Financials.
- Squarepoint's largest Q3 2024 buy was State Street Real Estate Select Sector SPDR ETF: 4,950,000 shares worth $221M.
- Squarepoint added most to iShares Core S&P 500 ETF in Q3 2024, an estimated $3B increase.
- Squarepoint's biggest Q3 2024 reduction was Bristol-Myers Squibb, cutting an estimated $184M.
- Squarepoint fully exited State Street SPDR S&P 500 ETF Trust in Q3 2024, selling an estimated $711M.
- Squarepoint's ten largest holdings make up 21% of its $63.9B portfolio in Q3 2024.
- Squarepoint opened 886 new positions and closed 823 in Q3 2024.
- Squarepoint's portfolio value rose 5.7% quarter-over-quarter to $63.9B.
Based on Squarepoint's 13F filing for Q3 2024, filed 14 Nov 2024.